Impact of IL6R genetic variants on treatment efficacy and toxicity response to sarilumab in rheumatoid arthritis
Authors' conclusion
These findings support the potential clinical value of SNPs, particularly rs4845625, as potentially useful biomarkers to predict response to sarilumab in patients with RA.
Study context
- Population
- Patients with RA treated with sarilumab
- Participants
- 62 patients
- Exposure
- IL6R gene single-nucleotide polymorphisms (SNP) genotypes and response to sarilumab
- Outcome
- Efficacy (satisfactory EULAR response, low disease activity by DAS28 and CDAI, improvement in DAS28 and CDAI) and toxicity responses
- Follow-up
- Six months after treatment initiation
Methodological detailsSix IL6R SNPs (rs12083537, rs11265618, rs4329505, rs2228145, rs4537545, rs4845625) genotyped; parametric tests
- Six IL6R SNPs (rs12083537, rs11265618, rs4329505, rs2228145, rs4537545, rs4845625) genotyped; parametric tests
Main finding
As reported in the abstract
Association of IL6R SNPs with response outcomes · six months
- Three SNPs (rs4845625, rs4329505 and rs11265618) significantly associated with response outcomes
Observational data: associations, not effects.
Safety
- All SNPs except rs12083537 had at least one significant association with dyslipidemia or hepatotoxicity
Original publication
Impact of IL6R genetic variants on treatment efficacy and toxicity response to sarilumab in rheumatoid arthritis. Arthritis Res Ther. Published 24 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →